1.
NEJM Evid
; 2(11): EVIDoa2300132, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38320527
RESUMO
A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label randomized clinical trial of nafamostat for noncritically ill patients with Covid-19.